Related Experiment Video
Updated: Aug 12, 2026

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
Published on: April 1, 2015
Extremely high avidity association of Fe(III) with the sickle red cell membrane
1Department of Medicine, University of Minnesota Medical School, Minneapolis, 55455, USA.
Abstract:
Red blood cells (RBCs) from patients with sickle cell anemia and thalassemia carry abnormal accumulations of molecular Fe(III) at the cytosol/membrane interface. The avidity of the red cell membrane for this iron has not been defined. Using open ghost membranes prepared from sickle RBC, we examined the ability of membrane-associated Fe(III) to resist removal by 15 chelators representing a 40-log range of affinities for Fe(III). Efficacy of chelators was compared with literature values for their idealized affinity for iron as represented by the cummulative stability constant (beta n), their effective stability constant reflecting affinity under biologic conditions (Keff), and an indicator of their ability to chelate Fe(III) in the presence of an insoluble phase of iron (Ksol). Deferoxamine, a very high affinity chelator having log beta n = 30.6, was found to be the lowest affinity chelator able to remove RBC membrane Fe(III). Regardless of chelator beta n, only those agents able to preserve log Keff > or = 12 were able to do so, indicating that the membrane's effective avidity for Fe(III) is on the order of 10(12). Additional confirmation that membrane avidity for Fe(III) is extremely high is found in the observation that only chelators having log Ksol > 0 were effective. Potential physiologic iron chelators in cytoplasm of pathologic red cells are unable to prevent or reverse iron accumulation on the membrane because they do not have sufficiently high affinity for iron. These data argue that RBC membrane Fe(III) is truly pathologic.
Insights
Red blood cells in sickle cell anemia and thalassemia have high iron accumulation. The red cell membrane avidly binds this iron, requiring high-affinity chelators for removal, indicating pathological iron.
Area of Science:
- Biochemistry
- Hematology
- Cell Biology
Background:
- Sickle cell anemia and thalassemia patients exhibit abnormal iron accumulation in red blood cells (RBCs).
- The iron is concentrated at the cytosol/membrane interface.
- The avidity of the RBC membrane for iron has not been previously defined.
Purpose of the Study:
- To define the avidity of the red cell membrane for Fe(III).
- To investigate the resistance of membrane-associated Fe(III) to removal by chelators.
- To understand the pathological iron accumulation in RBCs.
Main Methods:
- Open ghost membranes were prepared from sickle RBCs.
- Fifteen chelators with a 40-log range of Fe(III) affinities were used.
- Chelator efficacy was compared using stability constants (beta n), effective stability constants (Keff), and iron chelation in the presence of insoluble iron (Ksol).
Main Results:
- Deferoxamine (log beta n = 30.6) was the lowest affinity chelator capable of removing RBC membrane Fe(III).
- Only chelators with log Keff ≥ 12 could remove membrane Fe(III), indicating a membrane avidity of approximately 10(12).
- Chelators with log Ksol > 0 were effective, confirming high membrane avidity for Fe(III).
Conclusions:
- The red cell membrane exhibits extremely high avidity for Fe(III), on the order of 10(12).
- Physiological iron chelators are insufficient to prevent or reverse iron accumulation due to their lower affinity.
- Membrane-associated Fe(III) in these conditions is considered truly pathological.
Related Concept Videos
Affinity and Avidity
Protein Complex Assembly
Many viruses self-assemble into a fully functional unit using the infected host cell to...
Hemoglobin
When all four heme groups are bound to oxygen, the resulting molecule is called oxyhemoglobin. As a result, arterial blood...
Rh Blood Group
Blood Typing
Antigens are protein molecules that reside on the surface of red blood cells (RBCs). The ABO and Rh blood typing systems target antigens A,...
Oxygen Transport in the Blood

